Tags

Type your tag names separated by a space and hit enter

3D QSAR pharmacophore based virtual screening and molecular docking for identification of potential HSP90 inhibitors.
Eur J Med Chem. 2010 Jun; 45(6):2132-40.EJ

Abstract

Chemical features based 3D pharmacophore models were developed for HSP90 based on the known inhibitors using Discovery Studio V2.1. An optimal pharmacophore model was brought forth and validated using a decoy set, external test set and Fischer's randomization method. The best five features pharmacophore model, Hypo1, includes two hydrogen bond acceptors, three hydrophobic features, which has the highest correlation coefficient (0.93), cost difference (73.88), low RMS (1.24), as well as it shows a high goodness of fit and enrichment factor. Hypo1 was used as a 3D query for virtual screening to retrieve potential inhibitors from Maybridge and Scaffold databases. The hit compounds were subsequently subjected to molecular docking studies and finally, 36 compounds were obtained based on consensus scoring function.

Authors+Show Affiliations

Division of Applied Life Science (BK21 Program), Environmental Biotechnology National Core Research Center (EB-NCRC), Gyeongsang National University, Jinju 660-701, Republic of Korea.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20206418

Citation

Sakkiah, Sugunadevi, et al. "3D QSAR Pharmacophore Based Virtual Screening and Molecular Docking for Identification of Potential HSP90 Inhibitors." European Journal of Medicinal Chemistry, vol. 45, no. 6, 2010, pp. 2132-40.
Sakkiah S, Thangapandian S, John S, et al. 3D QSAR pharmacophore based virtual screening and molecular docking for identification of potential HSP90 inhibitors. Eur J Med Chem. 2010;45(6):2132-40.
Sakkiah, S., Thangapandian, S., John, S., Kwon, Y. J., & Lee, K. W. (2010). 3D QSAR pharmacophore based virtual screening and molecular docking for identification of potential HSP90 inhibitors. European Journal of Medicinal Chemistry, 45(6), 2132-40. https://doi.org/10.1016/j.ejmech.2010.01.016
Sakkiah S, et al. 3D QSAR Pharmacophore Based Virtual Screening and Molecular Docking for Identification of Potential HSP90 Inhibitors. Eur J Med Chem. 2010;45(6):2132-40. PubMed PMID: 20206418.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - 3D QSAR pharmacophore based virtual screening and molecular docking for identification of potential HSP90 inhibitors. AU - Sakkiah,Sugunadevi, AU - Thangapandian,Sundarapandian, AU - John,Shalini, AU - Kwon,Yong Jung, AU - Lee,Keun Woo, Y1 - 2010/02/04/ PY - 2009/10/08/received PY - 2009/12/22/revised PY - 2010/01/09/accepted PY - 2010/3/9/entrez PY - 2010/3/9/pubmed PY - 2010/7/28/medline SP - 2132 EP - 40 JF - European journal of medicinal chemistry JO - Eur J Med Chem VL - 45 IS - 6 N2 - Chemical features based 3D pharmacophore models were developed for HSP90 based on the known inhibitors using Discovery Studio V2.1. An optimal pharmacophore model was brought forth and validated using a decoy set, external test set and Fischer's randomization method. The best five features pharmacophore model, Hypo1, includes two hydrogen bond acceptors, three hydrophobic features, which has the highest correlation coefficient (0.93), cost difference (73.88), low RMS (1.24), as well as it shows a high goodness of fit and enrichment factor. Hypo1 was used as a 3D query for virtual screening to retrieve potential inhibitors from Maybridge and Scaffold databases. The hit compounds were subsequently subjected to molecular docking studies and finally, 36 compounds were obtained based on consensus scoring function. SN - 1768-3254 UR - https://www.unboundmedicine.com/medline/citation/20206418/3D_QSAR_pharmacophore_based_virtual_screening_and_molecular_docking_for_identification_of_potential_HSP90_inhibitors_ DB - PRIME DP - Unbound Medicine ER -